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respectively;- Presence of traces of other plant unsaponiﬁables
(like Colza unsaponiﬁables for example).
Conclusions: These nutraceutical products are therefore com-
pletely unrelated to the composition of the original pharmaceuti-
cal ASU. The quality of ASU is supported by a global know-how
concerning the qualitative management of the plant material from
it’s cultivation, extraction, hemisynthesis to it’s ﬁnal concentra-
tion. The original ASU alone may therefore claim a relationship
between the control of biodiversity, characterization of speciﬁc
structures and its pharmacological and clinical activity in os-
teoarthritis.
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Purpose: Cartilage biomarkers promise to advance our possi-
bilities to monitor articular cartilage damage and diseases by
non-invasive means. Complete medial meniscectomy has been
shown to lead to osteoarthritis(OA), in the human as in animal
models. In this study, complete medial meniscectomy was used
to investigate the potential of the collagenous biomarkers hydrox-
ylysylpyridinoline(HP) and lysylpyridinoline(LP) when measured
in urine.
Methods: New Zealand White rabbits (n = 32) had a complete
medial meniscectomy of their right knees using a medial parap-
atellar approach. Open surgery allowed a complete visualisation
of the joint structures at all timepoints of the procedure ensuring
a safe procedure. Postoperatively, the animals were housed in
cages. A group of 32 rabbits were used as unoperated controls.
8 rabbits of each group were sacriﬁced at 2, 4, 8 and 12 weeks.
Macroscopic mapping was performed on the right and left knee
joints using the scheme of the International Cartilage Repair
Society. Speciﬁc areas and sums of areas of all joint sites
were analysed for lesions. For microscopic evaluation, 4 µm
sections of the central tibial plateaus were stained with H&E
and Safranin O. Histologic analysis was performed with a ded-
icated grading system accounting for pathologic alterations of
proteoglycan content, matrix structure, cellularity, tidemark du-
plication, and osteophyte formation, basically a modiﬁed Mankin
scheme.
Urine samples were collected during the 24 hrs before surgery
and again during 24 hrs before each sacriﬁce time point. Mea-
surements of hydroxylysylpyridinoline (HP) and lysylpyridinoline
(LP) were performed with HPLC. Data were normalised to the
urinary creatinine. Ratios of the markers were calculated. Statis-
tical calculations were performed with SPSS using e.g. ANOVA,
Wilcoxon and Mann Whitney U tests.
Results: No signs of infection were noted during the postop-
erative course of the animals. Macroscopic lesions advanced
with time after meniscectomy. First degenerative changes were
already present at 2 weeks after surgery, with an increase in
number and size of lesions with time. Histologically, OA-like
lesions were present at all 4 examined timepoints.
The overall macroscopic, but not microscopic score correlated
inversely with the HP/creatinine ratio. The LP/creatinine ratio was
inversely correlated with either one.
Both HP/creatinine and LP/creatinine correlated inversely with
the overall histologic score. At the reported timepoints, both,
HP/creatinine and LP/creatinine ratios had generally lower mean
levels than the control animals. No simple timecourse which
might indicate a worsening osteoarthritic disease could be ob-
served with either ratio. This was also true for HP/LP.
Conclusions: Biomarkers have proven valuable in many bio-
logical systems and clinical situations eg in gastroenterology,
cardiology and oncology. Cartilage biomarkers are still under
development coming close to clinical utility. In this study, mea-
surements of HP and LP in the urine of rabbits after complete
medial meniscectomy did not show any simple signiﬁcant post-
operative changes. This was true for the respective ratios. Thus
we were not able to monitor the development of OA-like lesions
of the articular knee joint in a simple manner with these mark-
ers. Such somehow negative ﬁndings are part of a research
development which is still stimulating and will further our detailed
knowledge of cartilage and its diseases.
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Purpose: The CTX II assay has been developed to examine
the type II collagen telopeptide that is released from articular
cartilage into the systemic circulation. In human osteoarthritis
(OA) patients, the Urine Cartilaps® ELISA has been reported
to be useful in the prediction of the progression of OA. Since
type II collagen is well conserved across species, this assay
was modiﬁed by the manufacturers into the pre-clinical assay to
allow for a broader measuring range of CTX-II concentrations in
non-human urine. Horses are one of the few species in which
adequate volumes of paired synovial ﬂuid, serum, and urine
samples can be collected and compared to allow correlation of
this marker in these different ﬂuids. This may lead to translational
beneﬁt to human OA patients. The purpose of this report was to
validate the use of the Urine Pre-Clinical CTX II assay for use
with equine urine for future use with equine models of OA.
Methods: Urine Pre-Clinical Cartilaps® ELISAs (Nordic Bio-
science Diagnostics) were used for this validation study ac-
cording to manufacturer protocols. Internal quality control (QC)
samples were prepared using the highest concentration standard
provided by the manufacturer (99 ng/ml). To create QC samples,
fresh urine was collected from 6 normal horses via catheteriza-
tion. The samples were pooled together for further processing
and analysis. Pooled samples were spiked with a known amount
of standard to create samples with high, medium and low levels
of CTX II. The QC samples were used to determine the pre-
cision, speciﬁcity, sensitivity, accuracy, linearity of dilution, and
stability of this assay with equine urine. To ensure that the assay
could detect different biological activity, 3 previously stored urine
samples from normal and OA horses were analyzed.
Results: Reproducibility of the standard curve was evaluated
(n=6 plates) by computing mean optical density (OD) and per-
cent coefﬁcient of variation (% CV) at each standard concen-
tration. The overall mean inter-assay CV of the standard OD
values was 6.5% (range 1.6-24.4%). Samples exhibited accept-
able intra-assay and inter-assay precision over 3 plates with an
overall mean CV of 4.3% (range; 1.2-12.3%) and 7.2% (range;
4.7-9.7%), respectively. Parallelism and linearity of dilution of
equine serum sample dilutions (1:2, 1:4, 1:8, and 1:10) were
demonstrated (Figure 1). Lowest detection limit of the assay was
determined to be 1.38 ng/ml. Percent recovery was 90% for high,
90% for medium, and 95% for low QC samples. There was no
loss in the stability of the CTX II epitope out to 4 freeze/thaw
cycles. Differences in biological activity were identiﬁed when ex-
amining 3 samples from normal (3.23 ± 0.38 ng/ml) and OA
(2.25 ± 0.37 ng/ml) horses (P=0.03) (Figure 2).
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Figure 1. The linearity was analyzed by serially diluting the mixed QC samples
(MQC) at the following dilutions: 1:2, 1:4, 1:8, and 1:10. The observed concen-
tration was plotted against the reciprocal of the dilution to demonstrate linearity
of dilutions.
Figure 2. Differences in biological activity were identiﬁed when examining 3
samples from normal (3.23 ± 0.38 ng/ml) and OA (2.25 ± 0.37 ng/ml) horses.
Signiﬁcant differences between groups are represented as * P<0.05 using an
unpaired t-test.
Conclusions: Conclusions: The Urine Pre-Clinical Cartilaps®
ELISA is a reproducible and valid assay for use with equine
urine.
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Purpose: The purpose of this study was to compare two com-
mercially available kits and an inhouse method for measuring
Cartilage Oligomeric Protein (COMP) in human serum and as-
sessing their utility as biomarkers of knee osteoarthritis (kOA).
Methods: Blood was collected from 80 women participating in
the Johnston County Osteoarthritis Project. Serum was sepa-
Abstract 131 – Figure 1. Correlation by linear regression of Inhouse, Anamar, and Biovendor COMP (n=80).
rated immediately and stored at -80°C until analysis. Care was
taken to insure all samples had undergone the same limited num-
ber of freeze-thaws at the time of analysis. COMP concentrations
were determined using 3 sandwich ELISA methods: an inhouse
method utilizing MAb’s 16F12 and 17C10; and separate com-
mercially available kits from Biovendor (Modrice, Czech Rep.)
and Anamar (Gothenburg, Sweden). The Biovendor kit utilized
the same MAb’s as the inhouse method. The inhouse method
uses COMP puriﬁed from human cartilage as it’s standard while
Biovendor uses a recombinant human COMP (Gln21-Ala757).
Anamar uses human serum as a standard and results are ex-
pressed as U/L instead of ng/ml. OA status was determined
radiographically for each knee from posterior-anterior X-rays us-
ing the Synaﬂex positioning device, and a Kellgren-Lawrence
(KL) grade of ≥ 2 in at least one knee was considered to be
positive for kOA. Linear regression was used to compare the
results from the three methods. COMP concentrations were ln
transformed and one-way ANOVA was used to assess the asso-
ciations between COMP concentrations and knee OA laterality.
Results: Demographic and clinical characteristics are shown in
Table 1. Fifty percent had knee OA, and this was unilateral (1
knee) in 58% of those with kOA and bilateral (both knees) in
42% of those with kOA. Correlations between the methods (Fig.
1) were as follows: Biovendor to inhouse R2=0.897; Biovendor
to Anamar R2=0.249; Anamar to inhouse R2=0.210. All three
methods showed increasing ln COMP concentrations with the
number of OA affected knees (Fig. 2, see page S82), with the
following associations: inhouse p=0.0134; Biovendor p=0.0171;
Anamar p=0.289.
Table 1. Demographics and clinical characteristics of the sample, n=80 females
Mean age, yr (SD) 64 (9.7)
Mean BMI, kg/m2 (SD) 30.9 (6.8)
African American % 50
Knee OA % 50
Inhouse mean COMP ng/ml (range) 1608 (404-2929)
Biovendor mean COMP ng/ml (range) 872 (256-1582)
Anamar mean COMP U/L (range) 11.8 (5.7-18.6)
Conclusions: Correlation between the inhouse method and the
Biovendor kit was excellent, as expected since they use the
same MAb set. Correlation of the Biovendor or inhouse methods
with the Anamar kit was not as robust. The large differences
between mean values and ranges for the inhouse and Biovendor
assays are probably due to differences in the standards used.
Only the inhouse and Biovendor methods showed a signiﬁcant
association with kOA. All results were unadjusted for BMI, ethnic-
ity, or age, which may all be important confounders when using
COMP as a biomarker of OA. On the basis of these results, the
Biovendor COMP seems the best suited of the commercial kits
as a biomarker for kOA.
